Drug Trial Radar · NCT06876506
Identification of B Regulatory Cells by Flow Cytometry
Last checked: Nov 20, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Jan 21, 2026
Primary completion
May 31, 2027
Study completion Sep 30, 2027
Sponsor
- Lead sponsor
- Hull University Teaching Hospitals NHS TrustGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- Collaborators
- Health Education England, Wessex; University of Manchester
- First posted
- Mar 14, 2025
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this laboratory and observational study is to develop a test to quantify B-regulatory cells in blood. This will be used to detect changes in B-regulatory cell populations in pollen and insect venom allergic patients who are receiving routine allergen immunotherapy treatment. The primary question this study aims to answer is; 1). Are changes in blood B-regulatory cells associated with successful allergen immunotherapy treatment, and therefore do these changes suggest patients have developed a suitable level of allergen tolerance and reduction in their allergic symptoms upon re-exposure to the causal allergen. Patients will also be asked to complete quality of life questionnaire periodically throughout the study to determine if there are associations between variation in B-regulatory cell populations in blood and allergic symptoms experienced.
Conditions
- Pollen Allergy
- Venom Allergy
Interventions
VenepunctureDiagnostic test
Whole blood flow cytometry analysis of T-/B-lymphocyte subsets, regulatory B cells and regulatory T cells. Serological detection (immunoassay) of allergen-specific IgE and IgG4
Allergen Specific ImmunotherapyDrug
Test group receiving venom allergen immunotherapy as part of standard and routine care pathway (treatment commencement NOT for study purposes, cohort selected of those who are routinely commencing treatment).
Allergen Specific ImmunotherapyDrug
Test group receiving pollen allergen immunotherapy as part of standard and routine care pathway (treatment commencement NOT for study purposes, cohort selected of those who are routinely commencing treatment).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Utility of B regulatory cells as a biomarker of AIT treatment sucessTime frame: From enrolment to 1 year post commencing allergen-specific immunotherapy treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hull Teaching Hospital NHS Trust
Hull, East Yorkshire, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.